Insmed's 2025 Q1 Earnings Call: Unpacking Contradictions in Brensocatib Pricing and TPIP Development
Earnings DecryptMonday, May 19, 2025 6:10 pm ET

Market access and pricing strategy for brensocatib, pricing strategy and gross-to-net expectations, TPIP Phase III trial timeline, DPP1 inhibitor library expansion, and role of the 6-minute walk distance in the TPIP trial are the key contradictions discussed in Insmed's latest 2025Q1 earnings call.
Strong Financial Performance of ARIKAYCE:
- Insmed's ARIKAYCE showed remarkable year-over-year revenue growth, achieving double-digit increases in each geographic region for the sixth consecutive quarter.
- The growth was driven by strong volume trends due to increased new patient starts, particularly in Japan and Europe, where growth was around 50%.
Advancements in Clinical and Regulatory Milestones:
- Brensocatib, a key pipeline drug, made significant progress with its NDA filing for bronchiectasis, and the full results of the Phase 3 ASPEN trial were published in the New England Journal of Medicine.
- This progress was attributed to the clinical and regulatory team's efforts and the FDA's ongoing review process.
TPIP Program for PAH:
- The Phase 2 trial of TPIP in pulmonary arterial hypertension (PAH) is progressing, with the last patient's visit occurring in late March.
- The trial is expected to provide topline results in June, with significant excitement surrounding the potential impact on patient outcomes.
Launch Readiness for Brensocatib:
- Insmed's disease awareness website for bronchiectasis had over a million unique visits, and more than 53,000 self-identified patients engaged.
- These efforts are positioning Insmed for a frictionless launch of brensocatib in the U.S., with a focus on education and supporting patients through their healthcare journey.
Strong Financial Performance of ARIKAYCE:
- Insmed's ARIKAYCE showed remarkable year-over-year revenue growth, achieving double-digit increases in each geographic region for the sixth consecutive quarter.
- The growth was driven by strong volume trends due to increased new patient starts, particularly in Japan and Europe, where growth was around 50%.
Advancements in Clinical and Regulatory Milestones:
- Brensocatib, a key pipeline drug, made significant progress with its NDA filing for bronchiectasis, and the full results of the Phase 3 ASPEN trial were published in the New England Journal of Medicine.
- This progress was attributed to the clinical and regulatory team's efforts and the FDA's ongoing review process.
TPIP Program for PAH:
- The Phase 2 trial of TPIP in pulmonary arterial hypertension (PAH) is progressing, with the last patient's visit occurring in late March.
- The trial is expected to provide topline results in June, with significant excitement surrounding the potential impact on patient outcomes.
Launch Readiness for Brensocatib:
- Insmed's disease awareness website for bronchiectasis had over a million unique visits, and more than 53,000 self-identified patients engaged.
- These efforts are positioning Insmed for a frictionless launch of brensocatib in the U.S., with a focus on education and supporting patients through their healthcare journey.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet